RecruitingPhase 1Phase 2NCT07118891

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

A First-in-Human Phase 1/2 Study of ABCL635 in Healthy Participants and in Postmenopausal Women With Moderate-to-Severe Vasomotor Symptoms


Sponsor

AbCellera Biologics Inc.

Enrollment

136 participants

Start Date

Jun 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or hot flashes, and to postmenopausal women with moderate-to-severe VMS associated with menopause. The safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters of ABCL635 will be assessed in all study participants; the effects on frequency and severity of VMS will be assessed in postmenopausal women who experience moderate-to-severe symptoms.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Inclusion Criteria11

  • Good general health as determined through a review of their medical history and after conducting a general physical examination
  • Body weight ≥ 45 to ≤ 120 kg
  • Body mass index (BMI) between 18.5 kg/m2 and 35.0 kg/m2
  • Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped using nicotine products for at least 90 days prior to the first study drug administration)
  • Healthy man or a postmenopausal woman who is ≥ 40 and ≤ 75 years of age OR a postmenopausal woman with or without VMS and who is ≥ 40 and ≤ 75 years of age OR a postmenopausal woman who is ≥ 40 and ≤ 75 years of age seeking treatment for relief for VMS
  • If a woman:
  • has been compliant with local and/or national guidelines for breast cancer screening with documentation of a mammogram with normal/negative or no clinically significant findings. A screening mammogram may be conducted during study screening period, if needed
  • has spontaneous amenorrhea for at least 12 consecutive months; or spontaneous amenorrhea for at least 6 months with biochemical criteria of menopause (follicle-stimulating hormone \[FSH\] \> 40 IU/L); or had a bilateral oophorectomy \> 6 weeks prior to screening, or s/p hysterectomy at least 6 weeks prior to screening and meeting the biochemical criteria of menopause (FSH \> 40 IU/L)
  • If a man:
  • possess a testosterone concentration of ≥ 15 nmol/L at the time of screening
  • can procreate and agree to use one of the acceptable contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration OR is unable to procreate; defined as surgically sterile

Exclusion Criteria11

  • Pregnancy and/or lactation.
  • Has endometrial hyperplasia or history of abnormal uterine bleeding without an identified cause in the past 6 months
  • Previous or current history of a malignant tumor, except for non-melanoma skin cancer.
  • Seated pulse rate less than 50 beats per minute (bpm) or more than 100 bpm or a seated blood pressure \< 90/50 mmHg or \> 140/90 mmHg
  • eGFR \< 60 mL/min/1.73 m2
  • Severe hypersensitivity reactions (like angioedema) to any drugs.
  • Significant uncontrolled cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease.
  • Clinically significant ECG abnormalities
  • Presence or history of cardiogenic syncope in the past 6 months.
  • Use of any over-the-counter products (including supplements) containing testosterone or any medication (hormonal, prescription, over the counter, herbal, or natural) for the treatment of hot flashes during the screening period and throughout the study; must be discontinued at least 28 days prior to study drug administration
  • Employees of the sponsor or the investigator site and other individuals who are directly involved in the conduct of the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALABCL635

Participants will receive SC administrations of ABCL635

BIOLOGICALPlacebo

Participants will receive SC administration of placebo (5% dextrose solution)


Locations(10)

CaRe Clinics

Red Deer, Alberta, Canada

Mount Saint Joseph Hospital Clinical Trials Phase 1 Unit

Vancouver, British Columbia, Canada

Centricity Research

Toronto, Ontario, Canada

Centricity Research

Toronto, Ontario, Canada

Altasciences Company Inc.

Mount Royal, Quebec, Canada

Clinique RSF Inc.

Québec, Quebec, Canada

Diex Recherche Québec

Québec, Quebec, Canada

Diex Recherche Sherbrooke

Sherbrooke, Quebec, Canada

Diex Recherche Trois-Rivières

Trois-Rivières, Quebec, Canada

Diex Recherche Victoriaville

Victoriaville, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07118891


Related Trials